GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Everest Medicines Ltd (STU:6HN) » Definitions » 5-Year RORE %

Everest Medicines (STU:6HN) 5-Year RORE % : -81.68% (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Everest Medicines 5-Year RORE %?

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Everest Medicines's 5-Year RORE % for the quarter that ended in Dec. 2024 was -81.68%.

The industry rank for Everest Medicines's 5-Year RORE % or its related term are showing as below:

STU:6HN's 5-Year RORE % is ranked worse than
94.87% of 1150 companies
in the Biotechnology industry
Industry Median: -6.66 vs STU:6HN: -81.68

Everest Medicines 5-Year RORE % Historical Data

The historical data trend for Everest Medicines's 5-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Everest Medicines 5-Year RORE % Chart

Everest Medicines Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
5-Year RORE %
Get a 7-Day Free Trial - - - - -81.68

Everest Medicines Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
5-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 1.50 -81.68

Competitive Comparison of Everest Medicines's 5-Year RORE %

For the Biotechnology subindustry, Everest Medicines's 5-Year RORE %, along with its competitors' market caps and 5-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Everest Medicines's 5-Year RORE % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Everest Medicines's 5-Year RORE % distribution charts can be found below:

* The bar in red indicates where Everest Medicines's 5-Year RORE % falls into.


;
;

Everest Medicines 5-Year RORE % Calculation

Everest Medicines's 5-Year RORE % for the quarter that ended in Dec. 2024 is calculated as:

5-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 5-year -Cumulative Dividends per Share for 5-year )
=( -0.419--8.332 )/( -9.688-0 )
=7.913/-9.688
=-81.68 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 5-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Dec. 2024 and 5-year before.


Everest Medicines  (STU:6HN) 5-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 5-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Everest Medicines 5-Year RORE % Related Terms

Thank you for viewing the detailed overview of Everest Medicines's 5-Year RORE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Everest Medicines Business Description

Traded in Other Exchanges
Address
1168 West Nanjing Road, 16th Floor, CITIC Pacific Plaza, Jing’an District, Shanghai, CHN, 200041
Everest Medicines Ltd is a biopharmaceutical company that integrates discovery, licensing, clinical development, commercialization, and manufacturing of potentially novel or differentiated therapies and vaccines to address critical unmet medical needs initially in the Asia Pacific markets and eventually around the world. Its product pipeline includes; Nefecon (TarpeyoTM), EVER001 (previously known as XNW1011), PTX-COVID19-B, Eravacycline (Xerava), EVER206 (also known as SPR206), and others.

Everest Medicines Headlines

No Headlines